Last reviewed · How we verify
NCT02182986
Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children
trial testing transplant in Heart Transplant in 944 participants. Completed in 15 May 2019.
15 May 2019
Quick facts
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 944 |
| Start date | 14 August 2014 |
| Primary completion | 15 May 2019 |
| Estimated completion | 15 May 2019 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- transplant
- Immunosuppressive Drugs — full drug profile →
Conditions studied
- Heart Transplant — all drugs for Heart Transplant →
- Small Intestine Transplant — all drugs for Small Intestine Transplant →
- Kidney Transplant — all drugs for Kidney Transplant →
- Liver Transplant — all drugs for Liver Transplant →
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Who can join
Under 21, any sex, with Heart Transplant or Small Intestine Transplant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Solid organ transplantation is an important therapeutic option for children with a variety of end stage diseases. However, the same immunosuppressive medications that are required to prevent the child's immune system from attacking and rejecting the transplanted organ can predispose these individuals to developing a very serious cancer that is linked to Epstein-Barr virus (EBV).
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
Tajima T, Martinez OM, Bernstein D, Boyd SD, et al · · 2024 · cited 10× · PMID 38682750 · DOI 10.1111/petr.14763 -
High-dimensional profiling of pediatric immune responses to solid organ transplantation.
Rao M, Amouzgar M, Harden JT, Lapasaran MG, et al · · 2023 · cited 9× · PMID 37552988 · DOI 10.1016/j.xcrm.2023.101147 -
Mutations in latent membrane protein 1 of Epstein-Barr virus are associated with increased risk of posttransplant lymphoproliferative disorder in children.
Martinez OM, Krams SM, Robien MA, Lapasaran MG, et al · · 2023 · cited 5× · PMID 36796762 · DOI 10.1016/j.ajt.2023.02.014 -
Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder.
Sen A, Enriquez J, Rao M, Glass M, et al · · 2022 · cited 4× · PMID 36304469 · DOI 10.3389/fimmu.2022.994552 -
NKG2A+ NK cell cytotoxicity of Epstein-Barr virus infected B cells is mediated through the NKG2D and NKp30 activating receptors.
Pena JK, Zhang W, Badshah JS, Ledezma-Soto C, et al · · 2026 · cited 1× · PMID 41795284 · DOI 10.1093/jimmun/vkaf366
Verify or expand the search:
- PubMed search for NCT02182986
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of transplant
Trials testing the same drug.
- NCT03709576 — Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML · Phase 2 · terminated
Other recruiting trials for Heart Transplant
Currently open trials in the same condition.
- NCT06625073 — Randomized Trial of SGLT2i in Heart Transplant Recipients · Phase 4 · recruiting
- NCT05025774 — Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise · recruiting
- NCT06478017 — Belatacept in Heart Transplantation · Phase 2 · recruiting
- NCT07125703 — Observational Study With Additional Procedures: Metabolomic and Ultrastructural Findings of Allograft in Heart Transplan · active not recruiting
- NCT06426173 — Effect of Resistance Training in Patients on the Waiting List for Heart Transplant · NA · recruiting
Other National Institute of Allergy and Infectious Diseases (NIAID) trials
Trials by the same sponsor.
- NCT07216794 — Small Trial of Alendronate Impact on the Reservoir of HIV · Phase 2 · not yet recruiting
- NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
- NCT06987318 — A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) · Phase 1 · not yet recruiting
- NCT07124559 — A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of · Phase 1, PHASE2 · not yet recruiting
- NCT07342491 — Dasatinib for HIV-1 Reservoir Reduction · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02182986 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID)
- Last refreshed: 29 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02182986.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing